by Gregg A. Masters, MPH
This video via ASCO Post is sourced from ASCO’s 50th Annual Meeting in Chicago.
In this clip:
‘Dr. Jim Armitage, of the University of Nebraska Medical Center, speaks with Michael Pfreundschuh, of the Universitaetsklinikum des Saarlandes in Homburg, Germany about research presented at ASCO’s 50th Annual Meeting by the German High-Grade Lymphoma Study Group. In particular, Drs. Armitage and Pfreundschuh discuss the results of the phase II SEXIE-R-CHOP-14 trial in which researches found that increasing the dose of rituximab by one-third, from 375 mg/m2 to 500 mg/m2, eliminated any gender-related differences in survival outcomes among elderly patients with aggressive CD20+ B-cell lymphomas.’
For original source click here.